Q3 2024 Neogenomics Inc Earnings Call Transcript
Key Points
- NeoGenomics Inc (NEO) reported a 10% year-over-year revenue growth in Q3, with clinical business revenues growing by 14%, marking a record quarter in total test volume and revenues.
- The company achieved a 305% improvement in adjusted EBITDA from the prior year, marking five consecutive quarters of positive adjusted EBITDA.
- NGS (Next-Generation Sequencing) continues to be a key growth driver, increasing 26% and representing 31% of total clinical volume and revenue.
- NeoGenomics Inc (NEO) improved its lab turnaround time by 10% compared to Q3 of 2023, even with a significant increase in test volumes.
- The company launched new products like NEO AML Express and gained conditional approval in New York State for NEO Comprehensive Solid Tumor, enhancing its market position.
- The Advanced Diagnostics (ADX) segment saw a 10% revenue decline year-over-year, primarily due to international site closures and restructuring activities.
- There is a noted slowdown in market growth for large Pharma customers, impacting the performance of the Pharma business in 2024.
- The company anticipates a slight decline in margin in Q4 due to continued investments in sales force expansion and product development.
- NeoGenomics Inc (NEO) faces ongoing litigation challenges, including a settlement with Natera, which could impact future product development timelines.
- The company is experiencing some regional impact from hurricanes in Florida and the Carolinas, which may affect revenue in the fourth quarter.
Welcome to the NeoGenomics third-quarter, 2024 financial results conference call and webcast.
(Operator Instructions) Please note this conference is being recorded and an audio replay will be available on the company's website.
I will now hand the call over to Kendra Sweeney, Vice President of Investor Relations. You may begin.
Thank you, Jenny. Good morning, everyone and welcome to the NeoGenomics third-quarter, 2024 financial results call. With me today to discuss the results are Chris Smith, Chief Executive Officer; Jeff Sherman, Chief Financial Officer. Additional members of the management team are available for Q&A including Warren Stone, Chief Commercial Officer; Melody Harris, Chief Operations Officer and President of Informatics; Andrew Lukowiak, Chief Innovation Officer; Dr. Nathan Montgomery, Head of Medical; and Kareem Saad, Head of Strategy and Transformation.
This call is being simultaneously webcast. We'll be referring to a slide presentation that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
